The parties agreed to cooperate on matters related to the Bank’s participation in the company’s development and market positioning through comprehensive banking services. In particular, negotiations are underway on financing a large-scale investment project to construct new full-cycle vaccine production facilities at the Nanolek plant in the Kirov region.

The agreement was signed by Natalia Lyakhovich, First Vice President of Gazprombank, and Evgeny Barinov, CEO of Nanolek. Nanolek has been implementing an extensive investment program for several years, with a total value exceeding 15 billion rubles. As part of this program, new production capacities are being established at the biomedical complex in the Kirov region for the manufacture of vaccines against meningococcal infection, human papillomavirus (HPV), and varicella (chickenpox).

“The work is being carried out in accordance with the Strategy for the Development of Immunoprophylaxis of Infectious Diseases of the Russian Federation until 2035 and provides for the establishment of full-cycle production — from the active pharmaceutical ingredient (API) to the finished dosage form,” said Evgeny Barinov, CEO of Nanolek.

Currently, Nanolek, together with Gazprombank, is in the process of raising 10 billion rubles in borrowed funds under Government Decree No. 295 of the Russian Federation dated February 22, 2023, “On state support for organizations implementing investment projects aimed at the production of priority products.”

Gazprombank is considering financing the project and will provide support by offering effective financial solutions and ensuring the integration of state support measures.

“We see strong potential in Nanolek’s projects. The vaccines under development are among the candidates for inclusion in the National Immunization Schedule. The company demonstrates a high level of expertise and managerial competence, making it a reliable partner in implementing strategically important initiatives. These projects directly contribute to strengthening the technological sovereignty of the Russian Federation and to the development of the domestic pharmaceutical industry, including within the framework of the national project ‘New Health Preservation Technologies,’” said Natalia Lyakhovich, First Vice President of Gazprombank.